Cargando…

Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination

Anti-SARS-CoV-2 vaccines were developed in response to the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the BNT162b2 mRNA vaccine is effective, adverse effects have been reported. Here, we report a case of extranodal NK...

Descripción completa

Detalles Bibliográficos
Autores principales: Tachita, Takuto, Takahata, Takenori, Yamashita, Satoru, Ebina, Toru, Kamata, Kosuke, Yamagata, Kazufumi, Tamai, Yoshiko, Sakuraba, Hirotake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124685/
https://www.ncbi.nlm.nih.gov/pubmed/37093551
http://dx.doi.org/10.1007/s12185-023-03607-w
_version_ 1785029890670592000
author Tachita, Takuto
Takahata, Takenori
Yamashita, Satoru
Ebina, Toru
Kamata, Kosuke
Yamagata, Kazufumi
Tamai, Yoshiko
Sakuraba, Hirotake
author_facet Tachita, Takuto
Takahata, Takenori
Yamashita, Satoru
Ebina, Toru
Kamata, Kosuke
Yamagata, Kazufumi
Tamai, Yoshiko
Sakuraba, Hirotake
author_sort Tachita, Takuto
collection PubMed
description Anti-SARS-CoV-2 vaccines were developed in response to the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the BNT162b2 mRNA vaccine is effective, adverse effects have been reported. Here, we report a case of extranodal NK/T-cell lymphoma, nasal type (ENKL), of the left arm following BNT162b2 mRNA vaccination. A 73-year-old male presented with a lump in the left arm, which was the site where he received the BNT162b2 mRNA vaccine 3 months prior. He was treated with topical corticosteroids and debridement, but the tumor progressed. Additionally, fever, night sweats, and general fatigue were observed. Laboratory findings included thrombocytopenia, elevated lactate dehydrogenase, and soluble interleukin-2 receptor levels. Skin biopsy led to a diagnosis of ENKL. The patient was treated with a 50% dose of SMILE therapy and radiotherapy, resulting in regression of the tumor. It seems that latent Epstein–Barr virus (EBV)-infected NK/T cells were reactivated by vaccination and contributed to the onset of ENKL. This is the first report of ENKL after BNT162b2 mRNA vaccination. The present case highlights the possible risk of development of malignant lymphoma, including ENKL at the injection site, after BNT162b2 COVID-19 vaccination.
format Online
Article
Text
id pubmed-10124685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-101246852023-04-25 Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination Tachita, Takuto Takahata, Takenori Yamashita, Satoru Ebina, Toru Kamata, Kosuke Yamagata, Kazufumi Tamai, Yoshiko Sakuraba, Hirotake Int J Hematol Case Report Anti-SARS-CoV-2 vaccines were developed in response to the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the BNT162b2 mRNA vaccine is effective, adverse effects have been reported. Here, we report a case of extranodal NK/T-cell lymphoma, nasal type (ENKL), of the left arm following BNT162b2 mRNA vaccination. A 73-year-old male presented with a lump in the left arm, which was the site where he received the BNT162b2 mRNA vaccine 3 months prior. He was treated with topical corticosteroids and debridement, but the tumor progressed. Additionally, fever, night sweats, and general fatigue were observed. Laboratory findings included thrombocytopenia, elevated lactate dehydrogenase, and soluble interleukin-2 receptor levels. Skin biopsy led to a diagnosis of ENKL. The patient was treated with a 50% dose of SMILE therapy and radiotherapy, resulting in regression of the tumor. It seems that latent Epstein–Barr virus (EBV)-infected NK/T cells were reactivated by vaccination and contributed to the onset of ENKL. This is the first report of ENKL after BNT162b2 mRNA vaccination. The present case highlights the possible risk of development of malignant lymphoma, including ENKL at the injection site, after BNT162b2 COVID-19 vaccination. Springer Nature Singapore 2023-04-24 /pmc/articles/PMC10124685/ /pubmed/37093551 http://dx.doi.org/10.1007/s12185-023-03607-w Text en © Japanese Society of Hematology 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Tachita, Takuto
Takahata, Takenori
Yamashita, Satoru
Ebina, Toru
Kamata, Kosuke
Yamagata, Kazufumi
Tamai, Yoshiko
Sakuraba, Hirotake
Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
title Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
title_full Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
title_fullStr Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
title_full_unstemmed Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
title_short Newly diagnosed extranodal NK/T-cell lymphoma, nasal type, at the injected left arm after BNT162b2 mRNA COVID-19 vaccination
title_sort newly diagnosed extranodal nk/t-cell lymphoma, nasal type, at the injected left arm after bnt162b2 mrna covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10124685/
https://www.ncbi.nlm.nih.gov/pubmed/37093551
http://dx.doi.org/10.1007/s12185-023-03607-w
work_keys_str_mv AT tachitatakuto newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT takahatatakenori newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT yamashitasatoru newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT ebinatoru newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT kamatakosuke newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT yamagatakazufumi newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT tamaiyoshiko newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination
AT sakurabahirotake newlydiagnosedextranodalnktcelllymphomanasaltypeattheinjectedleftarmafterbnt162b2mrnacovid19vaccination